Granules India jumped 10.46% to Rs 155.80 after the company said its Visakhapatnam facility received European Commission Good Manufacturing Practice (EU GMP) approval.
Granules India Unit-V, high potent API and Finished Formulations manufacturing facility located at Visakhapatnam, Andhra Pradesh, India has received EU GMP approval.This approval is valid for three years. This facility was audited in January 2020 for good manufacturing practices of API and oral solid dosage. The announcement was made during market hours today, 7 April 2020.
Granules India is a growing pharmaceutical manufacturing company. The company produces finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).
On a consolidated basis, Granules India's net profit rose 6.2% to Rs 64.03 crore on 11.4% rise in net sales to Rs 703.96 crore in Q3 December 2019 over Q3 December 2018.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
